Skip to main content
No access
Review and Overview
Published Online: 1 October 2024

Antipsychotic Drugs: A Concise Review of History, Classification, Indications, Mechanism, Efficacy, Side Effects, Dosing, and Clinical Application

Publication: American Journal of Psychiatry

Abstract

The introduction of the first antipsychotic drug, chlorpromazine, was a milestone for psychiatry. The authors review the history, classification, indications, mechanism, efficacy, side effects, dosing, drug initiation, switching, and other practical issues and questions related to antipsychotics. Classifications such as first-generation/typical versus second-generation/atypical antipsychotics are neither valid nor useful; these agents should be described according to the Neuroscience-based Nomenclature (NbN). Antipsychotic drugs are not specific for treating schizophrenia. They reduce psychosis regardless of the underlying diagnosis, and they go beyond nonspecific sedation. All currently available antipsychotic drugs are dopamine blockers or dopamine partial agonists. In schizophrenia, effect sizes for relapse prevention are larger than for acute treatment. A major unresolved problem is the implausible increase in placebo response in antipsychotic drug trials over the decades. Differences in side effects, which can be objectively measured, such as weight gain, are less equivocal than differences in rating-scale-measured (subjective) efficacy. The criteria for choosing among antipsychotics are mainly pragmatic and include factors such as available formulations, metabolism, half-life, efficacy, and side effects in previous illness episodes. Plasma levels help to detect nonadherence, and once-daily dosing at night (which is possible with many antipsychotics) and long-acting injectable formulations are useful when adherence is a problem. Dose-response curves for both acute treatment and relapse prevention follow a hyperbolic pattern, with maximally efficacious average dosages for schizophrenia of around 5 mg/day risperidone equivalents. Computer apps facilitating the choice between drugs are available. Future drug development should include pharmacogenetics and focus on drugs for specific aspects of psychosis.

Get full access to this article

View all available purchase options and get full access to this article.

Information & Authors

Information

Published In

Go to American Journal of Psychiatry
Go to American Journal of Psychiatry
American Journal of Psychiatry
Pages: 865 - 878
PubMed: 39350614

History

Accepted: 13 August 2024
Published online: 1 October 2024
Published in print: October 01, 2024

Keywords

  1. Antipsychotic Drugs
  2. Psychosis
  3. Schizophrenia
  4. Efficacy
  5. Side Effects
  6. Psychopharmacology

Authors

Details

Stefan Leucht, M.D. [email protected]
Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Munich (Leucht, Priller); German Center for Mental Health, Munich (Leucht, Priller); Neuropsychiatry, Charité–Universitätsmedizin Berlin, and German Center for Neurodegenerative Disorders, Berlin (Priller); University of Edinburgh and UK Dementia Research Institute, Edinburgh (Priller); Department of Psychiatry, University of Illinois at Chicago (Davis).
Josef Priller, M.D.
Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Munich (Leucht, Priller); German Center for Mental Health, Munich (Leucht, Priller); Neuropsychiatry, Charité–Universitätsmedizin Berlin, and German Center for Neurodegenerative Disorders, Berlin (Priller); University of Edinburgh and UK Dementia Research Institute, Edinburgh (Priller); Department of Psychiatry, University of Illinois at Chicago (Davis).
John M. Davis, M.D.
Technical University of Munich, TUM School of Medicine and Health, Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, Munich (Leucht, Priller); German Center for Mental Health, Munich (Leucht, Priller); Neuropsychiatry, Charité–Universitätsmedizin Berlin, and German Center for Neurodegenerative Disorders, Berlin (Priller); University of Edinburgh and UK Dementia Research Institute, Edinburgh (Priller); Department of Psychiatry, University of Illinois at Chicago (Davis).

Notes

Send correspondence to Prof. Leucht ([email protected]).

Competing Interests

Prof. Leucht has received honoraria as an adviser, for lectures, and/or for educational material from Alkermes, Angelini, Apsen, Eisai, Gedeon Richter, Janssen, Karuna, Kynexis, Lundbeck, Medichem, Medscape, Merck Sharp and Dohme, Mitsubishi, Neurotorium, Novo Nordisk, Otsuka, Recordati, Roche, Rovi, Sanofi-Aventis, and Teva. Dr. Priller has a patent on erythropoietin variants and is a member of the SINAPPS2 Trial Steering Committee. Dr. Davis reports no financial relationships with commercial interests.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - American Journal of Psychiatry

PPV Articles - American Journal of Psychiatry

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

View options

PDF/EPUB

View PDF/EPUB

Full Text

View Full Text

Media

Figures

Other

Tables

Share

Share

Share article link

Share